Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Taysha Gene Therapies Inc (NASDAQ: TSHA) was $2.93 for the day, down -0.34% from the previous closing price of $2.94. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 3.08 million shares were traded. TSHA stock price reached its highest trading level at $3.045 during the session, while it also had its lowest trading level at $2.88.
Ratios:
Our analysis of TSHA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on July 11, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.
On April 09, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $9.Piper Sandler initiated its Overweight rating on April 09, 2024, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 30 ’25 when Manning Paul B bought 750,000 shares for $2.75 per share. The transaction valued at 2,062,500 led to the insider holds 2,841,704 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 799289408 and an Enterprise Value of 546292032. For the stock, the TTM Price-to-Sale (P/S) ratio is 98.68 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 67.46 whereas that against EBITDA is -6.207.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.96, which has changed by 0.27947593 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $3.31, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 11.86%, while the 200-Day Moving Average is calculated to be 40.17%.
Shares Statistics:
TSHA traded an average of 3.57M shares per day over the past three months and 2897890 shares per day over the past ten days. A total of 272.73M shares are outstanding, with a floating share count of 220.04M. Insiders hold about 19.34% of the company’s shares, while institutions hold 86.99% stake in the company. Shares short for TSHA as of 1753920000 were 38208254 with a Short Ratio of 10.71, compared to 1751241600 on 39852359. Therefore, it implies a Short% of Shares Outstanding of 38208254 and a Short% of Float of 16.409999.
Earnings Estimates
Taysha Gene Therapies Inc (TSHA) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.25 and -$0.4 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.42, with 5.0 analysts recommending between -$0.26 and -$0.58.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4.3M, resulting in an average revenue estimate of $7.61M. In the same quarter a year ago, actual revenue was $8.33M
